KUBANSKE VAKSINE PROTIV RAKA.

[Angelito]

postoje 2 vrste vaksine. Evo vama malo informaciju.

CIMAVax-EGF

EGF human recombinant Therapeutic Vaccine for the treatment of Lung cancer (nemikrocelulararni)
Therapeutic vaccine, immune stimulating.
Produced by: Centro de Inmunología Molecular
Internet: http://www.cim.sld.cu
Publications
Indicación terapéutica: CIMAvax-EGFhr is indicated for the treatment of advanced NSCLC (IIIb/IV), cancer.
Categoría farmacológica: Immune Stimulating
Presentation: -One bulb 2R containing 0,9 mL of EGFhr-p64k conjugated.
-One bulb 2R containing 0,8 mL of Montanide ISA 51
This product is the union of human recombinant Epidermal Growth Factor (EGFhr) with P64k recombinant protein, and Montanide ISA 51, forming a formulation with therapeutic quality for the treatment of patients with advanced lung cancer.


CIMAher (nimotuzumab)

nimotuzumab
ANTICANCER, CIMAher, is a humanized immunoglobulin, isotype IgG1 that binds the extracellular domain of the human EGF receptor (EGF-R). The antibody has an affinity constant of 109 L/mol for the binding to its receptor.

CIMAher blocks the binding of EGF to its receptor EGF-R, inhibits the activation of the tyrosine-kinase activity receptor induced by the binding of EGF and inhibits also the tumour growth in experimental animal models xenografted with human cancer cell lines.

CIMAher has a potent anti-angiogenic effect inhibiting the in vivo and in vitro production of the pro-angiogenic growth factors such as Vascular Endothelial Growth Factor (VEGF) and has important in vivo pro-apoptotic properties.

CIMAher induces an objective anti tumour response (partial or complete tumour remission). In combination with Radiotherapy the objective response is enhanced and no evidences of severe clinical toxicity were observed.
Produced by: Centro de Inmunología Molecular
Internet: http://www.cimaher.com
Publications
Indicación terapéutica: Is indicated in the treatment of advanced Squamous Cell Carcinoma of Head and Neck region with concurrent chemotherapy and / or radiotherapy. Pediatric patients with recurrent/refractory high grade malignant astrocytoma as monotherapy treatment of adult patients with Glioblastoma multiforme, with concurrent radiotherapy and in the treatment of esophagous tumors.
Categoría farmacológica: Steril injectable solution for I. V. use.
Presentation: Each 10 mL of sterile solution contains 50 mg of nimotuzumab, diluted in a buffered solution (pH=7.0 +/- 0.5) of monobasic sodium phosphate (18.0 mg), dibasic sodium phosphate (4.5 mg), sodium chloride (86.0 mg) and polysorbate 80 (2.0 mg) in water for injection.
This medicament is produced in compliance with current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP).
Humanized monoclonal antibody against epidermal growth factor receptor (EGFR)

[cicamaca]

Da li je ova druga vrsta vakcina za mikrocelularni cancer pluca ili ne?

[Angelito]

Da li je ova druga vrsta vakcina za mikrocelularni cancer pluca ili ne?

nA ZALOST PROTIV MIKROCELULARNOG NEMA NISTA.

[nadicab]

Da li neko moze da mi posalje kontakt bolnice sa Kube? Otac ima rak prostate,put do Kube i sve ostalo nam nije problem,samo nam treba kontakt.
Hvala unapred.

[Angelito]

Da li neko moze da mi posalje kontakt bolnice sa Kube? Otac ima rak prostate,put do Kube i sve ostalo nam nije problem,samo nam treba kontakt.
Hvala unapred.

Ako:

1. Patients diagnosed with primary tumor of epithelial origins with confirmationcitological and / or histological stage III or IV.
2. Patients who have completed the first line of treatment oncoespecific
3. That has been assessed objective response as stable disease, partial or complete remission 4 weeks after completion of primary treatment and do not have elapsed more than 8 weeks after completing treatment.
4. Having more than 18 years
5. Life expectancy of more than 3 months
6. No bearer of brain metastases
7. Female patients of childbearing age should not be pregnant
8. Not be receiving any other treatment for cancer
Mislim mogu da pomognem

[Biljaa]

Malo svežih informacija

http://www.blic.rs/Vesti/Svet/292012/Te ... Britancima

[J e l e n a]

Pozdrav svima.

Molim vas, da li neko ima informaciju kako doci do vakcine?

[coje]

pitanje : da li sam dobro razumeo ?
Kazete da vakcina eventualno lece samo ne-mikrocelijske tumore
A isto tako ne leci mikrocelijske tumore (tj. sitnocelijske tumore ili metastaze ili populano nazvani zlocudni tumor)

[J e l e n a]

"Vakcina CIMAvax je namenjena lecenju kansera pluca nemalih celija. Nize u postu navedeni su kriterijumu (na engleskom jeziku) koje pacijent treba da ispunjava kako bi se lecio istom. U bolnici Pradera, gde se ona primenjuje kod pacijenata iz inostranstva, rekli da se uzma 5 terapija od po 4 dnevne doze, na svakih 15 dana. Jedna doza iznosi oko 300 evra, a svih 20 oko 6.000, plus vakcinacija, svaka od oko 5 evra. Proverite sa doktorom u Srbiji da li pacijent boluje od kansera pluca nemalih celija i da li ispunjava uslove za dolazak. Tada bi trebalo pisati i kubanskim lekarima (sa histoloskim nalazom prevedenim na engleski ili spanski jezik) za saglasnost i zakazati termin. Objasnili su mi da potencijalizuje dejstvo kimo terapije i tako pomaze lecenju.

Vakcina moze da se prima ovde (Kuba) ili da po nju neko dodje, uz potvrdu srpskog doktora da ce je davati i potvrdu carine o dozvoljenom unosu vakcine. Vakcina putuje na ledu, te je potrebno da se po nju dodje, obzirom da ne postoji drugi nacin slanja."


APPROACHES OF SELECTION OF THE PATIENTS FOR RECEIVE TREATMENT WITH VACCINE CIMAvac-EGF

1. Patient with diagnosis of Primary Cancer of defined Lung as of non small Cells with histological confirmation in stadiums IIIB or IV.
2. Patient that have concluded the first line of treatment oncoespecífico (Chemo or Chemo/ Radiotherapy)
3. That the objective answer has been evaluated as stable Illness, complete or partial remission, according to the approaches established RECIST, 4 weeks after having concluded the primary treatment and that they have not lapsed more than 8 weeks after having concluded this treatment.
4. That he/she has more than 18 years.
5. That from the functional point of view he/she doesn't have negative approaches: complementary inside you limit normal of figures Haematological and Hemoquímicas.
6. Expectation of life of at least 3 months
7. Clinical State of OMS 0 At 2.
8. That he/she is not cerebral metastasis payee.
9. The feminine patients in fertile age should use contraceptive appropriate methods and to possess a test of pregnancy negative.
10. Patient that have signed the informed consent to receive this treatment vacunal.
11. The medical summary should be carried out by the doctor of attendance of the country in question where the expressed application of the treatment vacunal will be consigned.
12. He/she should be payee of a letter of authorization of the Regulatory Agency of the residence country for the tariff pertinent steps of entrance of the medication.
13. He/she should not be receiving any other treatment.

The patient should gather all these approaches that should be consigned in the * that you/he/she evaluates the Commission of Oncologists.

[aglaja]

jelena, da li ste slali nalaze u bolnicu i da li morate vi da imate nekoga ko bi doneo ili bi slali isto kao vidatox, po turistima? i da li sam dobro razumela da se dobija 4 nedelje posle PRVOG ciklusa hemoterapije?

[aglaja]

pitanje : da li sam dobro razumeo ?
Kazete da vakcina eventualno lece samo ne-mikrocelijske tumore
A isto tako ne leci mikrocelijske tumore (tj. sitnocelijske tumore ili metastaze ili populano nazvani zlocudni tumor)

lece makrocelijske, znam da tu spada adenokarcinom. ne lece mikrocelijske. svi su zlocudni - maligni ( i mikro i makro). lece iako postoje metastaze, ali ne ako su metastaze na mozgu.

[J e l e n a]

aglaja,

ja nisam lekar, tacnije nisam upucena u medicinu ni malo. Citam i ucim, kao i svi mi ovde. Molim Vas da tako i shvatite moja pisanija. Ono u sta sam sigurna, naznacicu.

Nisam slala nalaze iz razloga sto u stavci 1. pise da kanser treba da je primarni na plucima. Moj tata ima metastaze na plucima, a primarni je bio na debelom crevu.
Medjutim sada kad citam sve ovo ponovo, mozda sam ja tu malo naivna.

Pretpostavljam da mislite na stavku :"3. That the objective answer has been evaluated as stable Illness, complete or partial remission, according to the approaches established RECIST, 4 weeks after having concluded the primary treatment and that they have not lapsed more than 8 weeks after having concluded this treatment."
Sledece sam pronasla:
"RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve ("respond"), stay the same ("stable") or worsen ("progression") during treatments."
Ja prevodim ovako:
"Prema kriterijumu RECIST kanser kod pacijenta je stabilan (povukao se parcijalno ili delimicno). Ovakvo stanje je konstatovano 4 nedelje nakon terapije. I da nije isteklo vise od 8 nedelja od terapije."
Ako je prevod tacan to bi znacilo da da sa tretamanom treba da se krene izmdeju 4. i 8. nedelje nakon terapije.

Nisam sigurna u ovo, prvenstveno sto znam ljudi sa spanskih govornih podrucja umeju da ponekad okrenu smisao naopako na engleskom. Pokusacu da pronadjem na spanskom. Imam koga da pitam za prevod. Ali to tek u Nedelju ako stignem, a najkasnije u Ponedeljak.

[J e l e n a]

Ne mogu da pronadjem kriterijume koje pacijent treba da ispunjava kako bi se lecio vakcinom na spanskom jeziku
Mozda neko moze pomoci?